Simon Property Group reported strong Q2 2026 earnings with FFO of $3.29 per share beating estimates by 3.46% and raising full-year guidance. Despite solid operational metrics including 96% occupancy and 13.9% growth in retailer sales per square foot, the stock has declined 3.5% since the earnings report and underperformed the S&P 500. The company maintains a Zacks Rank #3 (Hold) rating with poor growth and momentum scores.
Quanta Services (PWR) reported strong Q2 2026 performance with a record $53B backlog, up from $48.5B in Q1. The company raised full-year 2026 revenue guidance to $39.3-$39.7B and adjusted EPS to $16.45-$16.95. Recent acquisitions are expected to add $1.2-$1.4B in revenues and $120-$140M in EBITDA. PWR stock has gained 51.4% year-to-date and currently holds a Zacks Rank #1 (Strong Buy) rating.
GE HealthCare Technologies has submitted its next-generation StarGuide GX digital SPECT/CT system for FDA 510(k) clearance following CE Mark approval in Europe. The system features dual-sided CZT detectors, NVIDIA RTX computing, and rapid collimator exchange, designed to support emerging radioligand therapies including alpha emitters like Actinium-225 and Lead-212. Despite the regulatory milestone, GEHC stock declined 3% following the announcement.
3M gained 9.1% over the past year, outperforming its industry despite a 26.4% decline. The company benefits from strong Safety and Industrial and Transportation and Electronics segments, with 2026 organic sales growth expected above 3.5%. However, high debt ($10.9B), weak consumer demand, litigation costs, and premium valuation (P/E of 17.59X) limit near-term prospects. Current shareholders should hold; new investors should await better entry points.
Bitcoin yield strategies have significantly compressed, with basis trades falling below Treasury rates since February 2026 and incentive-driven BTCfi TVL declining 74% from peak. The market is maturing with institutional products like BlackRock's BITA and Goldman Sachs' acquisition of NEOS Investments, shifting focus from highest rates to rates that fit individual holder profiles and tax situations.
Rocket Lab (RKLB) stock has declined 17.7% since its last earnings report in September 2026, underperforming the S&P 500. Despite the stock decline, the company delivered better-than-expected Q2 2026 results with a narrower loss, 62% year-over-year revenue growth to $234.1 million, and record backlog of $2.36 billion. The company raised Q3 guidance and ended the quarter with $2.4 billion in total liquidity. Analysts have raised estimates by 21.43% and assigned the stock a Zacks Rank #2 (Buy) rating, suggesting potential for above-average returns despite poor VGM scores.